Onward Med Nv

Good day and thank you for standing by. Welcome to the Onward Medical Q1 2026 results webcast and conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you will need to press star 1 and 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 and 1 again. Alternatively, you may submit your questions via the webcast. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Sebastian Cross, VP of Communications. Please go ahead.

Thank you, Sharon. Good morning, good afternoon, everyone, and welcome to Onward's webcast following the publication of our results for Q1 earlier today. Before we get started, as usual, please take a moment to read our disclaimer. This presentation includes forward-looking statements, which should be considered with the appropriate level of caution as outlined on this page. This deck and the recording of the webcast will be made available after our call. Today, I'm joined with three members of Onward's leadership team, Dave, our CEO, Sean Chiara, our chief commercial officer, and Aliki Boro, chief financial officer. Otherwise, we will present the results and key highlights from Q1 before opening the floor for questions. You may submit your questions orally or via the Q&A module of the platform. With that, I'll hand over to Dave.

Thank you, Seb. We had another successful quarter and off to a very good start for the year. We could continue to accelerate the launch of Archie X, achieving 2 million euros in revenue in the first quarter. that was comprised of 70 Archaic systems supplied for use in clinics and homes. That means that Archaic systems are now available in over 100 clinics across the U.S. and Europe as of the end of the first quarter. We also continued in our execution of the EmpowerBP pivotal trial for Arc IM to address blood pressure instability. In fact, the first participant was enrolled and implanted in the first quarter. And as we sit here today, we've now activated 12 sites within that study. We also advanced our pipeline, successfully implanting one additional patient in the Parkinson's disease blood pressure trial. That's an early feasibility study. And we initiated a new mobility feasibility study called IGER, in which we aim to enroll 12 subacute and chronic spinal cord injury patients. We also, last month, raised over 40 million euros in new equity capital, supported by a 25 million euro investment from EQT Life Sciences, extending our cash runway into Q1 of 2028. So now let's talk a bit more about the commercial traction with ArcheX. Those of you who are new to the company, this is ArcheX pictured in the presentation. This is an external stimulator. It stimulates the spinal cord through the skin to restore strength and sensation lost after spinal cord injury. Now I'd like to turn it over to Sean Chiara, our chief commercial officer.